Sanofi (NASDAQ:SNY) Stock Rated “Hold” by Sell-Side Brokerages

Shares of Sanofi (NASDAQ:SNY) have earned a consensus rating of “Hold” from the twenty-one analysts that are currently covering the company, Marketbeat reports. Twelve equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $53.00.

SNY has been the subject of a number of research analyst reports. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday. HSBC reaffirmed a “buy” rating on shares of Sanofi in a research report on Thursday, September 10th. Wolfe Research began coverage on Sanofi in a research note on Friday, October 9th. They issued a “peer perform” rating on the stock. Berenberg Bank reiterated a “buy” rating on shares of Sanofi in a research report on Monday, October 5th. Finally, BNP Paribas Exane raised shares of Sanofi from a “neutral” rating to an “outperform” rating and set a $57.00 target price for the company in a research note on Monday.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Tidal Investments LLC boosted its position in Sanofi by 21.5% in the 2nd quarter. Tidal Investments LLC now owns 165,289 shares of the company’s stock valued at $7,051,000 after buying an additional 29,283 shares during the period. Archford Capital Strategies LLC bought a new position in Sanofi in the 2nd quarter worth about $1,417,000. Assetmark Inc. grew its stake in Sanofi by 14.8% in the 1st quarter. Assetmark Inc. now owns 509,464 shares of the company’s stock worth $24,546,000 after acquiring an additional 65,796 shares in the last quarter. Mondrian Investment Partners LTD grew its stake in Sanofi by 2.3% in the 3rd quarter. Mondrian Investment Partners LTD now owns 5,652,139 shares of the company’s stock worth $233,038,000 after acquiring an additional 129,575 shares in the last quarter. Finally, AMG National Trust Bank purchased a new position in shares of Sanofi during the first quarter worth approximately $2,719,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Stock Up 0.2%

Shares of NASDAQ:SNY opened at $48.23 on Wednesday. Sanofi has a 1 year low of $39.07 and a 1 year high of $52.68. The business has a 50 day simple moving average of $42.44 and a two-hundred day simple moving average of $44.36. The firm has a market capitalization of $116.93 billion, a PE ratio of 23.88, a price-to-earnings-growth ratio of 1.32 and a beta of 0.31. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.12 and a quick ratio of 0.27.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 30th. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.56 by $0.48. Sanofi had a return on equity of 15.16% and a net margin of 8.70%. The firm had revenue of $17.25 billion for the quarter, compared to analysts’ expectations of $14.30 billion. During the same quarter in the prior year, the firm posted $2.91 earnings per share. The company’s quarterly revenue was up 16.2% on a year-over-year basis. On average, equities analysts predict that Sanofi will post 5.07 EPS for the current year.

Sanofi Company Profile

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.